These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 15680715)

  • 1. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients.
    Wahl A; Krumsdorf U; Meier B; Sievert H; Ostermayer S; Billinger K; Schwerzmann M; Becker U; Seiler C; Arnold M; Mattle HP; Windecker S
    J Am Coll Cardiol; 2005 Feb; 45(3):377-80. PubMed ID: 15680715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
    Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
    Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
    Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism.
    Martín F; Sánchez PL; Doherty E; Colon-Hernandez PJ; Delgado G; Inglessis I; Scott N; Hung J; King ME; Buonanno F; Demirjian Z; de Moor M; Palacios IF
    Circulation; 2002 Aug; 106(9):1121-6. PubMed ID: 12196339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism.
    Khositseth A; Cabalka AK; Sweeney JP; Fortuin FD; Reeder GS; Connolly HM; Hagler DJ
    Mayo Clin Proc; 2004 Jan; 79(1):35-41. PubMed ID: 14708946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exclusion of patients with arteriosclerosis reduces long-term recurrence rate of presumed arterial embolism after PFO closure.
    Dubiel M; Bruch L; Liebner M; Schmehl I; Winkelmann A; Rux S; Sonntag S; Wulff H; Grad MO; Kleber FX
    J Interv Cardiol; 2007 Aug; 20(4):275-81. PubMed ID: 17680857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter closure of patent foramen ovale associated with atrial septal aneurysm with Amplatzer Cribriform septal occluder.
    Musto C; Cifarelli A; Pandolfi C; De Felice F; Fiorilli R; Caferri G; Violini R
    J Invasive Cardiol; 2009 Jun; 21(6):290-3. PubMed ID: 19494408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism?
    Rigatelli G; Aggio S; Cardaioli P; Braggion G; Giordan M; Dell'avvocata F; Chinaglia M; Rigatelli G; Roncon L; Chen JP
    JACC Cardiovasc Interv; 2009 Jul; 2(7):655-62. PubMed ID: 19628189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
    Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
    J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm.
    von Bardeleben RS; Richter C; Otto J; Himmrich L; Schnabel R; Kampmann C; Rupprecht HJ; Marx J; Hommel G; Münzel T; Horstick G
    Int J Cardiol; 2009 May; 134(1):33-41. PubMed ID: 18715659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent events after percutaneous closure of patent foramen ovale.
    Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke.
    Butera G; Bini MR; Chessa M; Bedogni F; Onofri M; Carminati M
    Ital Heart J; 2001 Feb; 2(2):115-8. PubMed ID: 11256538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE; Thaler D; Brorson J; Heitschmidt M; Hijazi ZM;
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):524-8. PubMed ID: 14624434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events.
    Windecker S; Wahl A; Chatterjee T; Garachemani A; Eberli FR; Seiler C; Meier B
    Circulation; 2000 Feb; 101(8):893-8. PubMed ID: 10694529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical closure of combined symptomatic patent foramen ovale and atrial septum aneurysm for prevention of recurrent cerebral emboli.
    Klotz S; Tjan TD; Berendes E; Droste DW; Scheld HH; Schmid C
    J Card Surg; 2005; 20(4):370-4. PubMed ID: 15985142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.
    Hung J; Landzberg MJ; Jenkins KJ; King ME; Lock JE; Palacios IF; Lang P
    J Am Coll Cardiol; 2000 Apr; 35(5):1311-6. PubMed ID: 10758974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.